-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Zhanna Jumadilova, MD, MBA

Articles by Zhanna Jumadilova, MD, MBA

Persistence With Overactive Bladder Pharmacotherapy in a Medicaid Population

ByFadia T. Shaya, PhD, MPH,Steven Blume, MS,Anna Gu, MA,Teresa Zyczynski, PharmD, MBA, MPH,Zhanna Jumadilova, MD, MBA

July 15th 2005

Medical Costs After Initiation of Drug Treatment for Overactive Bladder: Effects of Selection Bias on Cost Estimates

ByNicole M. Nitz, PhD,Zhanna Jumadilova, MD, MBA,Theodore Darkow, PharmD,Jennifer R. Frytak, PhD,Tamara Bavendam, MD

July 15th 2005

Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive Bladder

BySujata Varadharajan, MS,Zhanna Jumadilova, MD, MBA,Prafulla Girase, MS,Daniel A. Ollendorf, MPH

July 15th 2005

Urinary Incontinence in the Nursing Home: Resident Characteristics and Prevalence of Drug Treatment

ByZhanna Jumadilova, MD, MBA,Teresa Zyczynski, PharmD, MBA, MPH,Barbara Paul, MD,Siva Narayanan, MS, MHS

July 15th 2005

Treatment of Overactive Bladder: A Model Comparing Extended-release Formulations of Tolterodine and Oxybutynin

ByEleanor M. Perfetto, PhD,Prasun Subedi, MS,Zhanna Jumadilova, MD, MBA

July 15th 2005

Latest Updated Articles

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

INCA033989 May Address Unmet Need in Mutant Calreticulin Myelofibrosis: Claire Harrison, MD